Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effects of Administration of Fostamatinib on Blood Concentrations of Warfarin in Healthy Subjects

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01311622
First received: February 21, 2011
Last updated: January 30, 2013
Last verified: January 2013

February 21, 2011
January 30, 2013
March 2011
May 2011   (final data collection date for primary outcome measure)
To determine PK parameters of R- and S-warfarin including but not limited to AUC and Cmax [ Time Frame: From pre-dose to 168 h post dose relative to each single warfarin dose ] [ Designated as safety issue: No ]
  • Pharmacokinetics of warfarin measured by AUC
  • Pharmacokinetics of warfarin measured Cmax
Same as current
Complete list of historical versions of study NCT01311622 on ClinicalTrials.gov Archive Site
  • To measure International Normalised Ratio (INR) following administration of warfarin [ Time Frame: From pre-dose to 168 h post dose relative to each single warfarin dose ] [ Designated as safety issue: No ]
  • To assess the steady-state pharmacokinetics of R406 (active metabolite of fostamatinib) by measuring AUCss, Cmax,ss, tmax,ss and CL/F [ Time Frame: From predose on Day 11 until 12 h post dose on Day 14 relative to fostamatinib dosing ] [ Designated as safety issue: No ]
    • Steady state Pharmacokinetics of R406 measured by AUCss
    • Steady state Pharmacokinetics of R406 measured by Cmax
    • Steady state Pharmacokinetics of R406 measured by ss
    • Steady state Pharmacokinetics of R406 measured by tmax
    • Steady state Pharmacokinetics of R406 measured by CL/F
  • Safety and tolerability will be measured with regard to adverse events, laboratory assessments, vital signs, physical examination, and 12-lead ECG will be recorded. [ Time Frame: From screening, Day -1 to Day 21 and follow up visit (Day 28) ] [ Designated as safety issue: Yes ]
    To examine the safety and tolerability of fostamatinib in combination with Warfarin: Adverse events, laboratory assessments, vital signs, physical examination, and 12-lead ECG
Same as current
Not Provided
Not Provided
 
Effects of Administration of Fostamatinib on Blood Concentrations of Warfarin in Healthy Subjects
An Open-Label, Single Centre Study to Assess the Pharmacokinetics and Pharmacodynamics of Warfarin When Co-Administered With Fostamatinib in Healthy Subjects

The purpose of this study is to determine whether fostamatinib influences the plasma concentration of warfarin and changes its blood thinning effect, and to investigate how safe and tolerable it is when administered with warfarin.

Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
  • Rheumatoid Arthritis
  • Healthy Subjects
  • Drug: warfarin
    2 single 25 mg doses of Warfarin (5 x 5 mg tablets) administered 14 days apart
    Other Name: Marevan
  • Drug: fostamatinib
    2 x 50 mg Fostamatinib tablets (100 mg) twice daily for 13 days
  • Experimental: warfarin
    Intervention: Drug: warfarin
  • Experimental: warfarin and fostamatinib
    Interventions:
    • Drug: warfarin
    • Drug: fostamatinib
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
15
May 2011
May 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Provision of informed consent prior to any study specific procedures (including genotyping screening sample for CYP2C9 and VKORC1).
  • Males or females (of non-childbearing potential) aged 18 to 55 years (inclusive)
  • Subjects must be negative for occult blood (stool card) prior to administration.
  • Body weight of at least 50 kg and body mass index (BMI) between 18 and 35 kg/m2 inclusive

Exclusion Criteria:

  • History of any clinically significant disease or disorder which, in the opinion of the Investigator, may put the subject at risk because of participation in the study, or influence the results of the study.
  • Healthy subject predicted to be most sensitive to warfarin based on CYP2C9 and VKORC1 genotypes.
  • A protein C and/or protein S deficiency.
  • Absolute neutrophil count of less than 2500/mm3 or 2.5 x 109/L
  • Previous treatment with warfarin for a clinical indication (ie, participation in a previous warfarin interaction study is acceptable).
Both
18 Years to 55 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT01311622
D4300C00013
Not Provided
AstraZeneca
AstraZeneca
Not Provided
Principal Investigator: James Ritter, BM BCh MRCP FRCP Quintiles, Phase 1 Unit, London
Study Director: Mark Layton, MD MRCP (UK) AstraZeneca
AstraZeneca
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP